Patents Represented by Attorney, Agent or Law Firm William M. Blackstone
  • Pseudorabies virus vaccine
    Patent number: 5196516
    Abstract: The present invention is concerned with a pseudorabies virus (PRV) vaccine comprising a polypeptide of the PRV glycoprotein gII or a fragment thereof which was shown to be the site of interaction of PRV neutralizing antibodies. Vector vaccines capable to express a polynucleotide fragment coding for such a polypeptide also form part of the present invention.
    Type: Grant
    Filed: July 21, 1989
    Date of Patent: March 23, 1993
    Assignee: Akzo N.V.
    Inventors: Christa S. Schreurs, Thomas C. Mettenleiter, Artur J. Simon, Noemi Lukacs, Hanns J. Rziha
  • Infectious bursal disease virus production in continuous cell lines
    Patent number: 5192539
    Abstract: Infectious bursal disease virus vaccine free of avian cell material comprising inactivated virus or live virus that induces a protective immune response when administered to poultry by noninjection means.
    Type: Grant
    Filed: May 11, 1989
    Date of Patent: March 9, 1993
    Assignee: Akzo N.V.
    Inventors: Piet Van Der Marel, Pieter G. Mooren
  • Phenoxyphenyl derivatives, compositions and methods of use thereof
    Patent number: 5190965
    Abstract: The invention concerns a phenoxyphenyl derivative having the formula ##STR1## wherein R is one or two halogen atoms; andA is CH.sub.2 NR.sub.1 R.sub.2 or 4,5-dihydro-1H-imidazole, in which R.sub.1 and R.sub.2 are independently selected from hydrogen and lower alkyl; ora pharmaceutically acceptable salt thereof.The compounds have long half-lives and can be used against depression.
    Type: Grant
    Filed: May 29, 1992
    Date of Patent: March 2, 1993
    Assignee: AKZO N.V.
    Inventors: Gerardus S. F. Ruigt, Dirk Leysen, Johannes H. Wieringa
  • 4-[4- or 6-(trifluoromethyl-2-pyridinyl)]-1-piperazinylalkyl substituted lactams
    Patent number: 5180726
    Abstract: The invention relates to neuroleptic/antidepressant 4-[4- or 6-(trifluoromethyl)-2-pyridinyl]-1-piperazinylalkyl substituted lactam derivatives having the general structure of formula I: ##STR1## wherein one of the groups R.sub.1 and R.sub.2 is CF.sub.3, and the other is hydrogen or CF.sub.3 ;R.sub.3 is hydrogen or (1-4 C) alkyl;n is an integer from 4 to 5; andm is an integer from 1 to 2; or pharmaceutically acceptable salts thereof.The invention also includes processes for making the compounds and their salts.
    Type: Grant
    Filed: October 17, 1991
    Date of Patent: January 19, 1993
    Assignee: Akzo N.V.
    Inventors: Patrick Carlier, Michel Combourieu, Claude Poisson, Andre J. Monteil
  • Tumor specific monoclonal antibodies
    Patent number: 5180814
    Abstract: A human monoclonal antibody having specificity for an epitope in a tumor associated antigen, said antibody produced by a cell line selected from the group consisting of Co6a3-1 (HB8493), Co7a4 (HB8494), Co28A32 (HB9380), Co16-86 (HB8496), and Co16-88 (HB8495).
    Type: Grant
    Filed: January 22, 1991
    Date of Patent: January 19, 1993
    Assignee: Akzo N.V.
    Inventors: Michael Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.
  • 5-isothiazolamine derivatives
    Patent number: 5179110
    Abstract: The invention relates to 5-isothiazolamine derivatives having the formula ##STR1## in which R.sub.1 is hydrogen, methyl, or ethyl, R.sub.2 and R.sub.3 are independently selected from hydrogen and alkyl, and the dotted line represents an optional bond, or a pharmaceutically acceptable acid addition salt thereof.The compounds have .alpha..sub.2 -adrenergic agonistic properties with little cardiovascular side-effects and minimal or no dopaminergic and cholinergic activity.
    Type: Grant
    Filed: July 3, 1991
    Date of Patent: January 12, 1993
    Assignee: Akzo N.V.
    Inventor: Thijs de Boer
  • Apparatus and method for detection of microorganisms
    Patent number: 5164796
    Abstract: An instrument for monitoring the color change of an indicator element sealed within a sterile vessel and exhibiting a color change in response to a change in the pH of CO.sub.2 level within the sterile vessel as a result of microbacterial growth within a specimen contained in the sterile vessel. The present invention includes means for continuously monitoring the absolute value of the pH and or CO.sub.2 level within the vessel and or monitoring the rate of change of the absolute value of the pH level.
    Type: Grant
    Filed: December 1, 1991
    Date of Patent: November 17, 1992
    Assignee: Akzo N.V.
    Inventors: James L. Di Guiseppi, Thurman C. Thorpe
  • Sulphated glycosaminoglycuronan with antithrombotic activity
    Patent number: 5164377
    Abstract: The present invention relates to sulphated glycosamino glycuronan with antithrombotic activity consisting essentially of salts of dermatan sulphate, chondroitin sulphate and heparan sulphate, characterized bya) an average molecular weight between 4000 and 8000 daltons;b) a nitrogen content between 2.4 and 3.0%;c) a sulphur content between 7.5 and 9.5%;d) a sodium content between 9 and 11%;e) a dermatan sulphate content between 5 and 25%;f) a chondroitin sulphate content less than 9%;g) an anti-Xa activity between 11 and 20 .mu./mg; andh) an antithrombin III dependent antithrombin activity of less than 1 .mu./mg.
    Type: Grant
    Filed: October 3, 1990
    Date of Patent: November 17, 1992
    Assignee: Akzo N.V.
    Inventors: Gijsbert W. K. Van Dedem, Francois E. A. Van Hou Denhoven, Dirk G. Meuleman, Huibert C. T. Moelker, Adrianus L. M. Sanders
  • Device and method for enhanced recovery and detection of microbial growth in the presence of antimicrobial substances
    Patent number: 5162229
    Abstract: The present invention relates to a device and method of detecting microorganisms in a rapid manner and increasing the number of microorganisms detected during the culturing of a sample by the addition of resinous and non-resin adsorbents and molecular sieves in the growth media. These agents have been found to neutralize or remove inhibitory and antimicrobial substances found in samples and media.
    Type: Grant
    Filed: July 19, 1991
    Date of Patent: November 10, 1992
    Assignee: Akzo N.V.
    Inventors: Thurman C. Thorpe, James L. DiGuiseppi, Richard C. Driscoll, James E. Turner, Michael J. Calandra
  • Method of contraception
    Patent number: 5150718
    Abstract: The invention relates to an implant of polymeric material which can release a contraceptive agent for a relatively long time when fitted subcutaneously or locally.
    Type: Grant
    Filed: February 14, 1992
    Date of Patent: September 29, 1992
    Assignee: Akzo N.V.
    Inventor: Hendrik De Nijs
  • Isochromane derivatives
    Patent number: 5137911
    Abstract: An isochromane derivative having the general formula I ##STR1## in which each of R.sub.1, R.sub.2, and R.sub.3 is one to four substituents independently selected from hydrogen, hydroxy, alkyl (1-4 C), alkoxy (1-4 C), halogen, or CF.sub.3, or represents a methylenedioxy group;R.sub.4 is selected from hydrogen or alkyl (1-4 C);Alk is an alkylene group with 1-4 carbon atoms;Alk' is an alkylene group with 2-4 carbon atoms, when R.sub.5 is selected from hydrogen or alkyl (1-4 C) and X is O or S; orAlk' is an alkylene group with 1-4 carbon atoms or a bond, when R.sub.5 is an alkyl (1-4 C) group and X is CH.sub.2 or a bond;or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 2, 1991
    Date of Patent: August 11, 1992
    Assignee: Akzo N.V.
    Inventors: Michael Combourieu, Jean-Claude Laigle
  • Pyridinylpiperazine derivatives
    Patent number: 5135931
    Abstract: Disclosed are compounds displaying improved preferential serotonin-1A binding activity. The claimed compounds have the formula: ##STR1## wherein R.sub.1 is selected from the group consisting of hydroxy, halogen, lower alkyl, lower alkoxy, and hydrogen;R.sub.2 is hydrogen or lower alkyl;X is CH or a nitrogen atom;ALK is a saturated, branched or unbranched, aliphatic hydrocarbon having from 1 to 7 carbon atoms; andZ is selected from the group consisting of hydrogen, halogen, hydroxy, trifluoromethyl, or lower alkyl;or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 10, 1991
    Date of Patent: August 4, 1992
    Assignee: Akzo N.V.
    Inventors: Patrick Carlier, Claude Poisson, Andre Monteil
  • Thiazole derivatives
    Patent number: 5128340
    Abstract: The invention relates to thiazole derivatives with the general formula I ##STR1## wherein R.sup.1 is halogen, CF.sub.3, CN, NO.sub.2, OH or C.sub.1 -C.sub.6 alkoxy;R.sup.2 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, aryl, C.sub.6 -C.sub.13 aralkyl, an unsubstituted amino group, a substituted amino group, or an amino group which is part of a 5- or 6-membered ring;R.sup.3 is C.sub.1 -C.sub.6 hydrocarbon, C.sub.6 -C.sub.13 aralkyl, C.sub.2 -C.sub.7 alkoxyalkyl or C.sub.1 -C.sub.13 acyl; and their pharmaceutically acceptable acid addition salts.These new compounds have .alpha..sub.2 -antagonist activity without dopamine agonist activity and as such are specifically useful for the treatment of depression and other related illnesses, e.g. for treating patients with anxiety disorders and cognitive disturbances.
    Type: Grant
    Filed: May 6, 1991
    Date of Patent: July 7, 1992
    Assignee: Akzo N.V.
    Inventors: Duncan R. Rae, Samuel G. Gibson
  • Hut-78 cell lines infected with HTLV-III which secrete gp160
    Patent number: 5122468
    Abstract: Human Immunodeficiency Virus (HIV) glycoprotein gp160 is produced in its native form using a clone of HUT78 cells chronically infected with HTLV-III.sub.451, known as 6D5.sub.451, and grown in serum-free medium. gp160 is also produced in its native form using a clone of 6D5.sub.451 that contains no HTLV-III virus.
    Type: Grant
    Filed: December 14, 1989
    Date of Patent: June 16, 1992
    Assignee: Akzo N.V.
    Inventors: Mangalasseril G. Sarngadharan, Vaniambadi S. Kalyanaraman
  • Method for producing native HIV gp160
    Patent number: 5116740
    Abstract: Human Immunodeficiency Virus (HIV) glycoprotein gp160 is produced in its native form using a clone of HUT78 cells chronically infected with HTLV-III.sub.451, and grown in serum-free medium.
    Type: Grant
    Filed: June 7, 1989
    Date of Patent: May 26, 1992
    Assignee: Akzo N.V.
    Inventors: Mangalasseril G. Sarngadharan, Vaniambadi S. Kalyanaraman
  • Aminoethylthiazole and aminoethyloxazole derivatives
    Patent number: 5116856
    Abstract: The invention relates to aminoethylthiazole and aminoethyloxazole derivatives with the general formula I ##STR1## wherein X is O or S;ALK is a hydrocarbyl (C.sub.2 -C.sub.6) group;R.sup.1 is a substituted or unsubstituted aryl group;R.sup.2 is a hydrogen, a hydrocarbyl (C.sub.1 -C.sub.6) group or an aralkyl (C.sub.7 -C.sub.13) group;R.sup.3 is a substituted or unsubstituted amino group;or their pharmaceutically acceptable acid addition salts.These new compounds are dopamine agonists with selectively for pre-synaptic dopamine receptors and, as such, are useful as anti-psychotics in the treatment of schizophrenia. The compounds are also useful in the treatment of hypertension, Parkinsonism and for the conditions of hyperprolactineamia, e.g. galactorrhea, menstrual disorders and amenorrhea.
    Type: Grant
    Filed: February 22, 1990
    Date of Patent: May 26, 1992
    Assignee: Akzo N.V.
    Inventors: Duncan R. Rae, Samuel G. Gibson
  • Tumor specific monoclonal antibodies
    Patent number: 5106738
    Abstract: A method for producing a human B-lymphocyte that is able to grow in cell culture and produces human monoclonal antibodies having binding specificity for tumor-associated antigens by exposing a human B-lymphocyte to a tumor cell antigen in a vaccine containing viable human tumor cells that have been made non-tumorigenic, and immortalizing the exposed B-lymphocyte by exposing to a transforming agent for sufficient time to transform the B-lymphocyte.
    Type: Grant
    Filed: January 25, 1989
    Date of Patent: April 21, 1992
    Assignee: AKZO NV
    Inventors: Michael G. Hanna, Jr., Martin V. Haspel, Jr., Herbert C. Hoover, Jr.
  • Dibenzodioxazecine and dibenzodioxaazacycloundecine derivatives
    Patent number: 5106839
    Abstract: Dibenzodioxazecine and dibenzodioxaazacycloundecine derivatives having the general formula I: ##STR1## or a pharmaceutically acceptable salt or nitrogen oxide thereof, in which R.sub.1, R.sub.2, R.sub.3 and R.sub.4 each represent independently hydrogen, hydroxy, halogen, cyano, alkyl, alkoxy or CF.sub.3 ;R.sub.5 represents hydrogen, alkyl, alkenyl, aralkyl, hydroxyalkyl or acyloxyalkyl; andn represents the number 1 or 2.The compounds in accordance with the invention are valuable C.N.S. (central nervous systems) active compounds, and in particular possess strong anti-psychotic properties with low propensity to induce extra-pyramidal side effects.
    Type: Grant
    Filed: October 19, 1990
    Date of Patent: April 21, 1992
    Assignee: Akzo N.V.
    Inventor: Johannes H. Wieringa
  • Device and method for detecting microorganisms
    Patent number: 5094955
    Abstract: An instrument and a sealable vessel for detecting the presence of microorganisms in a specimen, the vessel containing a liquid culture medium communicating with a sensor means containing an indicator medium therein. Changes in the indicator medium resulting from pH change or change in CO.sub.2 concentration in the medium are detected from outside the vessel.
    Type: Grant
    Filed: February 15, 1990
    Date of Patent: March 10, 1992
    Assignee: Akzo N.V.
    Inventors: Michael J. Calandra, James E. Turner, Thurman C. Thorpe, James L. DiGuiseppi, Richard C. Driscoll, Carmella S. Moody
  • Cartridge for blood monitor
    Patent number: D325975
    Type: Grant
    Filed: June 1, 1990
    Date of Patent: May 5, 1992
    Assignee: Akzo N.V.
    Inventors: Lanny Grade, Duane Kadavy, Larry Kerr